HCW Biologics Earnings Estimate

HCWB Stock  USD 0.99  0.06  5.71%   
By analyzing HCW Biologics' earnings estimates, investors can diagnose different trends across HCW Biologics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for HCW Biologics is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
 
Interest Hikes
HCW Biologics is projected to generate -0.63 in earnings per share on the 31st of December 2025. HCW Biologics earnings estimates show analyst consensus about projected HCW Biologics EPS (Earning Per Share). It derives the highest and the lowest estimates based on HCW Biologics' historical volatility. Many public companies, such as HCW Biologics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing HCW Biologics' earnings estimates, investors can diagnose different trends across HCW Biologics' analyst sentiment over time as well as compare current estimates against different timeframes. The current year's Gross Profit is expected to grow to about 965.4 K, whereas Pretax Profit Margin is projected to grow to (12.78). Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in child.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.

HCW Biologics Earnings per Share Projection vs Actual

About HCW Biologics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of HCW Biologics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current HCW Biologics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as HCW Biologics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for Next Year
Retained Earnings-90.5 M-86 M
Retained Earnings Total Equity-41 M-43 M
Earnings Yield(0.05)(0.05)
Price Earnings Ratio(20.75)(21.78)
Price Earnings To Growth Ratio(2.65)(2.52)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether HCW Biologics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of HCW Biologics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hcw Biologics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hcw Biologics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in child.
For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. Market participants price HCW higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive HCW Biologics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(16.41)
Revenue Per Share
0.68
Quarterly Revenue Growth
(0.99)
Return On Assets
(0.30)
Return On Equity
(277.26)
Investors evaluate HCW Biologics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating HCW Biologics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause HCW Biologics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, HCW Biologics' market price signifies the transaction level at which participants voluntarily complete trades.